Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.60 |
| ▸ | PPARG | P37231 | 8/20 | 0.60 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | PPARD | Q03181 | 2/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3719212 | 1.00 | PPARA (0.60) | PPARAPPARGCTSKITGB3ITGA2B | |
| SCHEMBL3719770 | 0.92 | PPARA (0.63) | PPARAPPARGCTSKITGB3ITGA2B | |
| SCHEMBL3719766 | 0.92 | PPARA (0.63) | PPARAPPARGCTSKITGB3ITGA2B | |
| SCHEMBL19068200 | 0.92 | PPARA (0.63) | PPARAPPARGCTSKITGB3ITGA2B | |
| SCHEMBL31407745 | 0.89 | CTSK (0.56) | PPARAPPARGCTSKITGB3ITGA2B | |
| SCHEMBL29055935 | 0.89 | CTSK (0.56) | PPARAPPARGCTSKITGB3ITGA2B | |
| SCHEMBL1374859 | 0.88 | CTSK (0.63) | PPARAPPARGCTSKCTSSPPARD | |
| SCHEMBL2781406 | 0.88 | CTSK (0.63) | PPARAPPARGCTSKCTSSPPARD | |
| SCHEMBL346311 | 0.88 | CTSK (0.63) | PPARAPPARGCTSKCTSSPPARD | |
| SCHEMBL5007433 | 0.88 | CTSK (0.57) | PPARAPPARGCTSKITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311798-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | HOFFMANN-LA ROCHE, INC. | 2010-12-09 | — | — | US | disclosed |
| WO-2010139707-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311798-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | TAAR1, TAAR5, NPY2R | PPARA 1384/4885PPARG 1013/4885CTSK 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.